Protagonist Therapeutics, Inc.
PTGX
Ранг среди акций
#2189
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Цена акции
$140.75
Рыночная капитализация
$9.11B
Изменение (1 день)
1.93%
Изменение (1 год)
91.50%
Страна
US
Торговля Protagonist Therapeutics, Inc. (PTGX)
Категория
Healthcare
История цены акций Protagonist Therapeutics, Inc. (PTGX)
Наивысшая цена закрытия: $138.71 2026-10-01
Наименьшая цена закрытия: $11.34 2016-08-01
Наименьшая цена закрытия: $11.34 2016-08-01
История цены акций Protagonist Therapeutics, Inc. с 2016 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2026 (TTM) | 21.89% |
| 2025 | 119.26% |
| 2024 | 92.93% |
| 2023 | 131.51% |
| 2022 | -72.05% |
| 2021 | 46.48% |
| 2020 | 203.82% |
| 2019 | 9.00% |
| 2018 | -65.01% |
| 2017 | -15.57% |
| 2016 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $536.74 | 25.87% |
US
|
|
| $227.23 | 746.28% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $881.75 | 8.30% |
NL
|
